Breast Cancer

Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer

CRANBURY, N.J. & SHANGHAI — Accutar Biotechnology, Inc., a clinical stage biotechnology company fo...

  • 2 years ago

Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0682 in ER-Positive Breast Cancer

BROOKLYN, N.Y. & SHANGHAI - Accutar Biotechnology, Inc., a clinical stage biotechnology company focu...

  • 2 years ago

Find us here